Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 4 days agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks· 2 days agoFree Report) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% ...
Allogene secures $15 million grant for cancer trial By Investing.com
Investing.com· 15 hours agoThe funding is earmarked to support the Phase 1 TRAVERSE trial, which is evaluating the safety and...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 1 day agoOutside the U.S., KEYTRUDA growth was driven by continued uptake in earlier-stage cancers, including high-risk, early stage, triple-negative breast...
Analysis identifies 50 new genomic regions associated with kidney cancer risk
Medical Xpress· 13 hours agoIn a new analysis of genetic susceptibility to kidney cancer, an international team of researchers has identified 50 new areas across the genome that are associated with the risk of developing ...
New study provides genomic insights into kidney cancer risk
National Cancer Institute· 22 hours agoIn a new analysis of genetic susceptibility to kidney cancer, an international team of researchers...
Moriah Elyse Kerns - Valencia County News-Bulletin
Valencia County News-Bulletin· 2 days agoMoriah Elyse Kerns, age 27, a resident of Los Lunas, passed away on April 20, 2024, as a result of renal cell carcinoma. Moriah was pursuing ...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 2 days agoPatients will receive Keytruda or Keytruda plus the vaccine after bladder or kidney removal. Bladder...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 1 day agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
FOX 23 News Albany· 2 days agoFirst-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced...
